These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25450818)

  • 1. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
    Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
    Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
    Esteghamati A; Azizi R; Ebadi M; Noshad S; Mousavizadeh M; Afarideh M; Nakhjavani M
    Exp Clin Endocrinol Diabetes; 2015 May; 123(5):289-95. PubMed ID: 25607338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?
    Berezin A
    Diabetes Metab Syndr; 2016; 10(3):169-70. PubMed ID: 26869171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial.
    Esteghamati A; Noshad S; Rabizadeh S; Ghavami M; Zandieh A; Nakhjavani M
    Regul Pept; 2013 Mar; 182():1-6. PubMed ID: 23328000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus.
    Mori K; Emoto M; Araki T; Yokoyama H; Lee E; Teramura M; Koyama H; Shoji T; Inaba M; Nishizawa Y
    Metabolism; 2008 Sep; 57(9):1248-52. PubMed ID: 18702951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial.
    Esteghamati A; Rezvani S; Khajeh E; Ebadi M; Nakhjavani M; Noshad S
    J Endocrinol Invest; 2014 Dec; 37(12):1211-8. PubMed ID: 25138574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
    Esposito K; Maiorino MI; Di Palo C; Gicchino M; Petrizzo M; Bellastella G; Saccomanno F; Giugliano D
    Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
    Erdem G; Dogru T; Tasci I; Bozoglu E; Muhsiroglu O; Tapan S; Ercin CN; Sonmez A
    Diabetes Res Clin Pract; 2008 Nov; 82(2):214-8. PubMed ID: 18778865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
    Ramachandran A; Snehalatha C; Salini J; Vijay V
    J Assoc Physicians India; 2004 Jun; 52():459-63. PubMed ID: 15645955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse Association of Peripheral Orexin-A with Insulin Resistance in Type 2 Diabetes Mellitus: A Randomized Clinical Trial.
    Zarifkar M; Noshad S; Shahriari M; Afarideh M; Khajeh E; Karimi Z; Ghajar A; Esteghamati A
    Rev Diabet Stud; 2017; 14(2-3):301-310. PubMed ID: 29145540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between osteoprotegerin, fetuin-A, carotid intima media thickness, and urinary albumin excretion in Type 2 diabetes.
    Koluman BU; Mutluay R; Derici UB; Arinsoy T; Senlik Z; Bahar B; Sancak B; Oktan SO; Sindel S
    Clin Nephrol; 2013 Jul; 80(1):9-16. PubMed ID: 23458176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.